| Literature DB >> 33330691 |
Cinzia Marianelli1, Daniela Ape2, Federica Rossi Mori2.
Abstract
Mycobacterium avium-intracellulare complex infections are becoming an increasing concern in veterinary medicine because they affect livestock, wildlife, and companion animals. Here we describe the isolation, molecular typing, and antibiotic susceptibility testing of the causative agent of a rare case of generalized mycobacteriosis in a crossbred dog. Mycobacterial colonies were isolated from a popliteal lymph node aspirate sample and molecular typed by SNPs typing of the genes gyrB and rpsA, the 3' region of the hsp65 gene and the internal transcribed spacer (ITS), and MIRU-VNTR analysis. Colonies were also tested in vitro against the macrolide clarithromycin and other drugs, using a resazurin microdilution assay, in order to provide the most appropriate treatment for the dog. Results from SNPs typing of gyrB and ITS, as well as from MIRU-VNTR analysis suggested the isolation of a single strain of M. avium subsp. hominissuis (Mah). On the other hand, SNP typing of rpsA revealed DNA polymorphisms that led colonies to cluster into two groups. The presence of two distinct strains of Mah has been assumed. All colonies, regardless of the nucleotide sequence of rpsA, were found to be sensitive to all of the drugs tested except for ethambutol. Although the therapy administered was adequate, the dog's overall clinical status worsened progressively and the animal died 8 months later. In conclusion, we report on the isolation of Mah from a dog with generalized mycobacteriosis.Entities:
Keywords: MIRU-VNTR analysis; Mycobacterium avium subsp. hominissuis; SNPs typing; antimicrobial susceptibility; disseminated infection; dog
Year: 2020 PMID: 33330691 PMCID: PMC7672039 DOI: 10.3389/fvets.2020.569966
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Primers used for PCR and sequencing.
| F 5′- GCAGACGCCAAAGTCATTGT -3′ R 5′- TCGAACTCGTCGTGAATCCC -3′ | 353 | ( | |
| F 5′- CTTCTCGAATCCCTCGAGCC -3′ R 5′- CGCCTGATCCTGTCCAAGAA -3′ | 933 | ( | |
| 3′ | F 5′- CGGTTCGACAAGGGTTACAT -3′ R 5′- ACGGACTCAGAAGTCCATGC -3′ | 1059 | ( |
| ITS | F 5′- TTGTACACACCGCCCGTCA -3′ R 5′- TCTCGATGCCAAGGCATCCA -3′ | ~600 | ( |
Antimicrobial agents tested and proposed MIC breakpoints for MAC.
| Clarithromycin | ≤16 | 32 | ≥64 | ( |
| Streptomycin | ≤16 | 32 | ≥64 | ( |
| Amikacin | ≤16 | 32 | ≥64 | ( |
| Rifampicin | ≤1 | - | ≥2 | ( |
| Ciprofloxacin | ≤1 | 2 | ≥4 | ( |
| Doxycycline | ≤1 | 8 | ≥16 | ( |
| Ethambutol | ≤2 | 4 | ≥8 | ( |
| Linezolid | ≤8 | 16 | ≥32 | ( |
S, susceptible; I, intermediate; R, resistant.
Standard laboratory guidelines for in vitro susceptibility testing for MAC isolates are only reported for clarithromycin (as primary agent) and linezolid (as secondary agent). Clarithromycin serves as a class drug for all newer macrolides, especially azithromycin. According to CLSI recommendations, clarithromycin was tested in Middlebrook 7H9 broth at pH 6.8.
Nucleotide and amino acid changes in the rpsA gene of a total of 22 colonies (the initial four colonies and the subsequent 18 colonies).
| A | 6 | GAT (D) | GCC (A) | GAG (E) | GAC (D) |
| B | 16 | AAT (N) | ACC (T) | CAG (Q) | AAC (N) |
Figure 1Drug susceptibility profile the primary broth culture. A–F: sample triplicates. G, H: sample quadruplicates. S, susceptible; I, intermediate; R, resistant. Lines A–C, columns 1–3: 16.0 (S), 32.0 (I), and 64.0 (R) μg ml−1 for clarithromycin; columns 4–7: 8.0 (S), 16.0 (S), 32.0 (I), and 64.0 (R) μg ml−1 for streptomycin; columns 8–10: 16.0 (S), 32.0 (I), and 64.0 (R) μg ml−1 for amikacin; column 11: positive control containing no drug (+); column 12: negative control containing uninoculated medium (–). Lines D–F, columns 1, 2: 1.0 (S) and 2.0 (R) μg ml−1 for rifampicin; columns 3–5: 1.0 (S), 2.0 (I), and 4.0 (R) μg ml−1 for ciprofloxacin; columns 6–8: 1.0 (S), 8.0 (I), 16.0 (R) μg ml−1 for doxycycline; columns 9–12: 2.0 (S), 4.0 (I), 8.0 (R), 16.0 (R) μg ml−1 for ethambutol. Lines G, H, columns 1, 2, 3, 4, 5, 6: 8.0 (S), 16.0 (I), 32.0 (R) μg ml−1 for linezolid.